T Cell Epitope-Containing Peptides of the Major Dog Allergen Can f 1 as Candidates for Allergen Immunotherapy1

One prerequisite for developing peptide-based allergen immunotherapy is knowing the T cell epitopes of an allergen. In this study, human T cell reactivity against the major dog allergen Can f 1 was investigated to determine peptides suitable for immunotherapy. Seven T cell epitope regions (A–G) were found in Can f 1 with specific T cell lines and clones. The localization of the epitope regions shows similarities with those of the epitopes found in Bos d 2 and Rat n 1. On average, individuals recognized three epitopes in Can f 1. Our results suggest that seven 16-mer peptides (p15–30, p33–48, p49–64, p73–88, p107–122, p123–138, and p141–156), each from one of the epitope regions, show widespread T cell reactivity in the population studied, and they bind efficiently to seven HLA-DRB1 molecules (DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301, and DRB1*1501) predominant in Caucasian populations. Therefore, these peptides are potential candidates for immunotherapy of dog allergy.

[1]  J. Partanen,et al.  The DR4–DQ8 haplotype and a specific T cell receptor Vβ T cell subset are associated with absence of allergy to Can f 1 , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[2]  P. Cullinan,et al.  Determination of the T cell epitopes of the lipocalin allergen, Rat n 1 , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[3]  S. Auriola,et al.  Assessment of recombinant dog allergens Can f 1 and Can f 2 for the diagnosis of dog allergy , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  S. Durham,et al.  Mechanisms of immunotherapy. , 2004, The Journal of allergy and clinical immunology.

[5]  C. L. Hardy,et al.  Blocking antibodies in allergen immunotherapy: the Yin and Yang , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  N. Bercovici,et al.  An Altered Self-Peptide with Superagonist Activity Blocks a CD8-Mediated Mouse Model of Type 1 Diabetes1 , 2004, The Journal of Immunology.

[7]  Hans-Georg Rammensee,et al.  MHC ligands and peptide motifs: first listing , 2004, Immunogenetics.

[8]  T. Virtanen,et al.  Mammalian allergens. , 2004, Clinical allergy and immunology.

[9]  G. Schneider,et al.  The Crystal Structure of the Major Cat Allergen Fel d 1, a Member of the Secretoglobin Family* , 2003, Journal of Biological Chemistry.

[10]  B. Maillère,et al.  The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells. , 2003, European journal of immunology.

[11]  Philippa Marrack,et al.  Epitope dominance, competition and T cell affinity maturation. , 2003, Current opinion in immunology.

[12]  Alain Sanson,et al.  HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity1 , 2002, The Journal of Immunology.

[13]  A. Kay,et al.  Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial , 2002, The Lancet.

[14]  S. Matsushita,et al.  Interaction among human leucocyte antigen–peptide–T cell receptor complexes in cow's milk allergy: the significance of human leucocyte antigen and T cell receptor–complementarity determining region 3 loops , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[15]  Kim Bottomly,et al.  The Potency of TCR Signaling Differentially Regulates NFATc/p Activity and Early IL-4 Transcription in Naive CD4+ T Cells1 , 2002, The Journal of Immunology.

[16]  A. Närvänen,et al.  Lipocalin allergen Bos d 2 is a weak immunogen. , 2002, International immunology.

[17]  Amos Bairoch,et al.  The PROSITE database, its status in 2002 , 2002, Nucleic Acids Res..

[18]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[19]  A. Kay,et al.  Allergen-Derived T Cell Peptide-Induced Late Asthmatic Reactions Precede the Induction of Antigen-Specific Hyporesponsiveness in Atopic Allergic Asthmatic Subjects1 , 2001, The Journal of Immunology.

[20]  S. Matsushita,et al.  Identification of β‐lactoglobulin‐derived peptides and class II HLA molecules recognized by T cells from patients with milk allergy , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[21]  Virander S. Chauhan,et al.  Flexibility in MHC and TCR Recognition: Degenerate Specificity at the T Cell Level in the Recognition of Promiscuous Th Epitopes Exhibiting No Primary Sequence Homology , 2001, The Journal of Immunology.

[22]  A. Ménez,et al.  Complementarity and redundancy of the binding specificity of HLA‐DRB1, ‐DRB3, ‐DRB4 and ‐DRB5 molecules , 2001, European journal of immunology.

[23]  D R Flower,et al.  The lipocalin protein family: structural and sequence overview. , 2000, Biochimica et biophysica acta.

[24]  R. Mäntyjärvi,et al.  Lipocalins as allergens. , 2000, Biochimica et biophysica acta.

[25]  Dominique Charron,et al.  HLA-DR Restricted Peptide Candidates for Bee Venom Immunotherapy , 2000, The Journal of Immunology.

[26]  W. van Eden,et al.  Modulation of Th2 Responses by Peptide Analogues in a Murine Model of Allergic Asthma: Amelioration or Deterioration of the Disease Process Depends on the Th1 or Th2 Skewing Characteristics of the Therapeutic Peptide1 , 2000, The Journal of Immunology.

[27]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[28]  R. Mäntyjärvi,et al.  Allergy to lipocalins: a consequence of misguided T-cell recognition of self and nonself? , 1999, Immunology today.

[29]  A. Sidoli,et al.  Cutting edge: identification of novel T cell epitopes in Lol p5a by computational prediction. , 1999, Journal of immunology.

[30]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[31]  P. Vilja,et al.  T cell epitopes of a lipocalin allergen colocalize with the conserved regions of the molecule. , 1999, Journal of immunology.

[32]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[33]  J. Bousquet,et al.  Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. , 1998, The Journal of allergy and clinical immunology.

[34]  N. Komiyama,et al.  T cell epitopes in Japanese cedar (Cryptomeria japonica) pollen allergens: choice of major T cell epitopes in Cry j 1 and Cry j 2 toward design of the peptide-based immunotherapeutics for the management of Japanese cedar pollinosis. , 1998, Journal of immunology.

[35]  Sastre,et al.  Olive pollen allergy: searching for immunodominant T‐cell epitopes on the Ole e 1 molecule , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[36]  R. Aalberse,et al.  The major dog allergens, Can f 1 and Can f 2, are salivary lipocalin proteins: cloning and immunological characterization of the recombinant forms , 1997, Immunology.

[37]  Dominique Charron,et al.  HLA : genetic diversity of HLA functional and medical implication , 1997 .

[38]  K. B. Hafner,et al.  Treatment of cat allergy with T-cell reactive peptides. , 1996, American journal of respiratory and critical care medicine.

[39]  R. Garman,et al.  Definition of the human T-cell epitopes of Fel d 1, the major allergen of the domestic cat. , 1996, The Journal of allergy and clinical immunology.

[40]  J. Lamb,et al.  T-cell responses to allergens: epitope-specificity and clinical relevance. , 1996, Immunology today.

[41]  J. Pelkonen,et al.  Complementary DNA cloning of the predominant allergen of bovine dander: a new member in the lipocalin family. , 1996, The Journal of allergy and clinical immunology.

[42]  A. Sette,et al.  Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo , 1995, The Journal of experimental medicine.

[43]  N. Najafian,et al.  Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. , 1995, Journal of immunology.

[44]  A. Finnegan,et al.  Interference with the binding of a naturally processed peptide to class II alters the immunodominance of T cell epitopes in vivo. , 1994, Journal of immunology.

[45]  G. Pani,et al.  Cord blood mononuclear cell responsiveness to beta-lactoglobulin: T-cell activity in 'atopy-prone' and 'non-atopy-prone' newborns. , 1994, International archives of allergy and immunology.

[46]  R. O’Hehir,et al.  Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice , 1993, The Journal of experimental medicine.

[47]  J. Greenstein,et al.  Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  B. Wüthrich,et al.  T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. , 1993, Journal of immunology.

[49]  M. Gefter,et al.  Immunodominance: intermolecular competition between MHC class II molecules by covalently linked T cell epitopes. , 1992, Journal of immunology.

[50]  P. Matricardi,et al.  Processing of tetanus toxin by human antigen-presenting cells. Evidence for donor and epitope-specific processing pathways. , 1989, Journal of immunology.

[51]  M. Bekoff,et al.  Relative contribution of "determinant selection" and "holes in the T-cell repertoire" to T-cell responses. , 1989, Proceedings of the National Academy of Sciences of the United States of America.